文献速递肝病消化道肿瘤与早癌

肝细胞癌表观遗传改变的全面研究识别潜在治疗靶点

A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
PubMed 文献 · J Hepatol · 2019-03-15

研究利用癌症基因组图谱365例肝细胞癌数据,分析表观遗传修饰酶的分子临床相关性,并在体外和体内评估表观遗传抑制剂的治疗潜力。研究发现表观遗传酶遗传改变和异常表达常见,JmjC抑制剂可逆转侵袭性基因表达程序并抑制肿瘤生长,还识别并验证了由CENPA、KIF20A、PLK1和NCAPG组成的4基因预后特征。

要点

  • 表观遗传修饰酶的遗传改变和异常表达在肝细胞癌中常见,并与不良预后相关。
  • 靶向溴结构域、赖氨酸甲基转移酶和JmjC赖氨酸去甲基化酶的表观遗传抑制剂可降低肝细胞癌侵袭性。
  • 泛JmjC抑制剂JIB-04在荷瘤小鼠中具有强效抗肿瘤作用,并识别验证了4基因预后特征。

核心结论

  • 肝细胞癌中识别的表观遗传改变可用于预测预后,并界定可能从JmjC抑制剂治疗中获益的高危患者亚组。

研究设计与样本

  • 利用癌症基因组图谱365例肝细胞癌患者的资料,研究表观遗传修饰酶的分子临床相关性,并在体外和体内评估表观遗传抑制剂的治疗潜力,采用RNA测序分析及其与癌症基因组图谱数据集中表达和临床数据的相关性来识别由JmjC抑制剂正常化的表达程序。

主要发现

  • 表观遗传酶的遗传改变、异常表达以及肿瘤表达与患者不良预后之间的相关性在肝细胞癌中是常见事件。
  • 靶向溴结构域(JQ-1)、赖氨酸甲基转移酶(BIX-1294和LLY-507)和JmjC赖氨酸去甲基化酶(JIB-04、GSK-J4和SD-70)的表观遗传抑制剂可降低肝细胞癌侵袭性。
  • 泛JmjC抑制剂JIB-04在荷瘤小鼠中具有强效抗肿瘤作用。
  • 用JmjC抑制剂处理的肝细胞癌细胞显示出与抑制细胞增殖和诱导细胞死亡相关的表达程序的重叠变化。
  • JmjC抑制可逆转一种侵袭性肝细胞癌基因表达程序,该程序在肝细胞癌患者中也发生改变;被JmjC抑制剂下调的若干基因在肿瘤实质中高表达,且其高表达与不良预后相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A causal link has recently been established between epigenetic alterations and hepatocarcinogenesis, indicating that epigenetic inhibition may have therapeutic potential. We aimed to identify and target epigenetic modifiers that show molecular alterations in hepatocellular carcinoma (HCC). METHODS: We studied the molecular-clinical correlations of epigenetic modifiers including bromodomains, histone acetyltransferases, lysine methyltransferases and lysine demethylases in HCC using The Cancer Genome Atlas (TCGA) data of 365 patients with HCC. The therapeutic potential of epigenetic inhibitors was evaluated in vitro and in vivo. RNA sequencing analysis and its correlation with expression and clinical data in the TCGA dataset were used to identify expression programs normalized by Jumonji lysine demethylase (JmjC) inhibitors. RESULTS: Genetic alterations, aberrant expression, and correlation between tumor expression and poor patient prognosis of epigenetic enzymes are common events in HCC. Epigenetic inhibitors that target bromodomain (JQ-1), lysine methyltransferases (BIX-1294 and LLY-507) and JmjC lysine demethylases (JIB-04, GSK-J4 and SD-70) reduce HCC aggressiveness. The pan-JmjC inhibitor JIB-04 had a potent antitumor effect in tumor bearing mice. HCC cells treated with JmjC inhibitors showed overlapping changes in expression programs related with inhibition of cell proliferation and induction of cell death. JmjC inhibition reverses an aggressive HCC gene expression program that is also altered in patients with HCC. Several genes downregulated by JmjC inhibitors are highly expressed in tumor vs. non-tumor parenchyma, and their high expression correlates with a poor prognosis. We identified and validated a 4-gene expression prognostic signature consisting of CENPA, KIF20A, PLK1, and NCAPG. CONCLUSIONS: The epigenetic alterations identified in HCC can be used to predict prognosis and to define a subgroup of high-risk patients that would potentially benefit from JmjC inhibitor therapy. LAY SUMMARY: In this study, we found that mutations and changes in expression of epigenetic modifiers are common events in human hepatocellular carcinoma, leading to an aggressive gene expression program and poor clinical prognosis. The transcriptional program can be reversed by pharmacological inhibition of Jumonji enzymes. This inhibition blocks hepatocellular carcinoma progression, providing a novel potential therapeutic strategy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Bayo J, Fiore EJ, Dominguez LM, et al. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets. J Hepatol. 2019. PMID: 30880225. doi:10.1016/j.jhep.2019.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。